Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.

Revenue projections:

Revenue projections for SUVENPHAR
Revenue projections for SUVENPHAR

The projected decline in SUVENPHAR's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 0.000000
forwardPE 56.269436
debtToEquity 1.945000
earningsGrowth 0.755000
revenueGrowth 0.397000
grossMargins 0.627760
operatingMargins 0.316950
trailingEps 10.900000
forwardEps 0.000000

SUVENPHAR's high forward PE suggests the stock may be overvalued, which could prevent further price gains and lead to a correction. This parameter should be carefully evaluated in context with other fundamental data to ensure a balanced view.
Positive earnings and revenue growth for Suven Pharmaceuticals Limited suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
Suven Pharmaceuticals Limited's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.

Price projections:

Price projections for SUVENPHAR
Price projections for SUVENPHAR

SUVENPHAR's present price relative to projections does not indicate any obvious risks or opportunities. This balanced situation suggests a period of stability, where investors may find it prudent to maintain their current strategies until more information becomes available.

Recommendation changes over time:

Recommendations trend for SUVENPHAR
Recommendations trend for SUVENPHAR


SUVENPHAR has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view SUVENPHAR as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.